Navigation Links
Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation

Study Showing Results of Tengion Neo-Bladder Augment(TM) Featured in

September Issue of Regenerative Medicine

EAST NORRITON, Pa., Sept. 18 /PRNewswire/ -- Tengion Inc., a clinical stage regenerative medicine company focused on the development of neo-organs and neo-tissues, today announced that the results of a preclinical research study conducted with its Tengion Neo-Bladder Augment(TM) were published in the September issue of the Regenerative Medicine, Vol. 3, Issue 5. The paper, "Long-term durability, tissue regeneration and neo-organ growth during skeletal maturation with a Neo-Bladder Augmentation Construct" was co-authored by Tengion scientists Manuel J. Jayo, D.V.M., Ph.D., Deepak Jain, Ph.D., John W. Ludlow, Ph.D., Richard Payne, Ph.D., Belinda J. Wagner, Ph.D., and Timothy A. Bertram, D.V.M., Ph.D. along with Gordon McLorie, MD from Wake Forest University Baptist Medical Center. The article can be accessed via the website

The preclinical study, in which either a Neo-Bladder Augment or the subject's own native urinary bladder was surgically implanted following an 80% cystectomy and evaluated clinically at one, three, six, nine, 12, 18 and 24 months - showed that the Tengion Neo-Bladder Augment regained and maintained native bladder histology by three months. The study also demonstrated that the Neo-Bladder Augment regained baseline capacity at three to six months and baseline compliance by 12-24 months. Importantly, the Neo-Bladder Augment continued to adapt in size and function with overall animal growth, or skeletal maturation.

"The results of this study are very encouraging for our overall Neo-Bladder Augment program and, specifically, for our ongoing Neo-Bladder Augment pediatric clinical trial. The children with spina bifida in that trial are continuing to grow and mature and our goal is for the Neo-Bladder Augment to demonstrate durability and the ability to adapt to growth-related changes - as it has done in this pre-clinical model," said Dr. Bertram, Senior Vice President, Science and Technology of Tengion, "Tengion is truly excited to continue to share positive research results that help to further advance our neo-organ pipeline, and continue to validate our Autologous Organ Regeneration Platform(TM)."

About Tengion

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create a functional neo-organ or neo-tissue that is designed to catalyze the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies.

SOURCE Tengion Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
2. Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
3. Tengion Appoints Jeff Randall to Board of Directors
4. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
5. Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
6. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
7. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
8. Social Network for Scientists Marks Ten Years Online
9. Scientists synthesize memory in yeast cells
10. Scientists synthesize memory in yeast cells
11. University of Leicester scientists discover technique to help friendly bacteria
Post Your Comments:
(Date:11/24/2015)... ... 2015 , ... The Academy of Model Aeronautics (AMA), led by its Executive ... Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , FPV racing ... this type of racing and several new model aviation pilots have joined the community ...
(Date:11/24/2015)... 2015 --> ... released by Transparency Market Research, the global non-invasive prenatal ... of 17.5% during the period between 2014 and 2022. ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... market to reach a valuation of US$2.38 bn by ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna ... announced today that the remaining 11,000 post-share consolidation ... Purchase Warrants (the "Series B Warrants") subject to ... exercised on November 23, 2015, which will result ... After giving effect to the issuance of such ...
(Date:11/24/2015)... Urdorf, Switzerland (PRWEB) , ... November 24, 2015 ... ... the plant and the environment are paramount. Insertion points for in-line sensors can ... TOLEDO has developed the InTrac 781/784 series of retractable sensor housings , ...
Breaking Biology Technology:
(Date:11/19/2015)... 19, 2015  Although some 350 companies are actively ... a few companies, according to Kalorama Information. These include Roche ... the market share of the 6.1 billion-dollar molecular testing ... Market for Molecular Diagnostic s .    ... still controlled by one company and only a handful ...
(Date:11/17/2015)... , November 17, 2015 ... 19 novembre  2015.  --> Paris , ... --> DERMALOG, le leader de l,innovation biométrique, a ... fois passeports et empreintes sur la même surface de ... passeports et l,autre pour les empreintes digitales. Désormais, un ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
Breaking Biology News(10 mins):